Testing an anti-inflammatory PET imaging treatment in memory loss
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This Phase 2 study tests whether targeting “neuroinflammation” (inflammation in the brain) can help in Alzheimer’s disease and related memory disorders. You may help researchers by doing several brain scans (including a special PET/CT scan) along with MRI and amyloid imaging to understand what’s happening in the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 60 years old or older
- Have one of the study diagnosis categories (Alzheimer’s, mild cognitive impairment, or dementia related to Lewy bodies—based on their group testing)
- Be able to do the required set of brain check-ins: at least 2 testing sessions with their partner clinics/studies
- Have or plan to have an amyloid PiB PET scan and an MRI brain scan within about 6 months of your first ER176 PET/CT scan
- Be able to sign consent yourself, or have a legally authorized representative sign for you
- Be able to lie still on the scanning table for 20 minutes without needing to move
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a special PET scan that uses a radioactive tracer (18F-mFBG) to see how much it is taken up by the heart. The goal is to help tell Lewy body disease (Parkinson's or Lewy body dementia) apart from other brain disorders.
This study uses a special PET scan to look for inflammation in the brains of people with Alzheimer's or related dementias. It may help researchers understand how inflammation affects memory and thinking problems.
This Phase 1 study tests a PET scan to measure inflammation-related changes in the brain using a medication called ketoprofen. It may help researchers understand which people with certain brain diseases could benefit from treatments aimed at inflammation.
This study uses a special PET brain scan to look at two types of brain immune cells in people with Alzheimer’s. It may help researchers better understand Alzheimer’s and how these cells change over time.
This Phase 2 study uses repeated brain MRI scans to track “microglial activation,” which is a marker of brain immune/inflammation activity, in different Alzheimer’s-related conditions. It may help researchers understand how brain inflammation changes over time and differs between people with these clinical variants.
This trial tests a monoclonal antibody therapy—a lab-made protein—to see if it can slow Alzheimer's symptoms. You may qualify if you have early Alzheimer's or mild cognitive impairment with a positive PET scan, and you can't have other major health issues like uncontrolled diabetes or heart problems.
Hear when a new Alzheimer Dementia (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.